$10.03
1.18%
Nasdaq, Sep 12, 10:07 pm CET
ISIN
US82835W1080
Symbol
SPRY

Silverback Therapeutics Stock price

$10.03
-6.63 39.80% 1M
-2.28 18.52% 6M
-0.52 4.93% YTD
-2.60 20.59% 1Y
+4.77 90.68% 3Y
-10.97 52.24% 5Y
-10.97 52.24% 10Y
-10.97 52.24% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.12 1.18%
ISIN
US82835W1080
Symbol
SPRY
Industry

Key metrics

Basic
Market capitalization
$991.2m
Enterprise Value
$751.1m
Net debt
positive
Cash
$240.1m
Shares outstanding
98.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.8 | 11.9
EV/Sales
6.7 | 9.0
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
73.1%
Return on Equity
3.1%
ROCE
-22.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$112.3m | $83.4m
EBITDA
$-58.7m | $-150.2m
EBIT
$-59.3m | $-176.2m
Net Income
$-48.0m | $-151.8m
Free Cash Flow
$-53.4m
Growth (TTM | estimate)
Revenue
22,368.0% | -6.4%
EBITDA
-3.6% | -4,941.5%
EBIT
-4.6% | -5,621.5%
Net Income
-7.1% | -1,997.8%
Free Cash Flow
-20.7%
Margin (TTM | estimate)
Gross
93.7%
EBITDA
-52.3% | -180.1%
EBIT
-52.8%
Net
-42.7% | -182.0%
Free Cash Flow
-47.5%
More
EPS
$-0.5
FCF per Share
$-0.5
Short interest
34.7%
Employees
165
Rev per Employee
$540.0k
Show more

Is Silverback Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Silverback Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Silverback Therapeutics forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Silverback Therapeutics forecast:

Buy
92%
Hold
8%

Financial data from Silverback Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
112 112
22,368% 22,368%
100%
- Direct Costs 7.06 7.06
-
6%
105 105
-
94%
- Selling and Administrative Expenses 150 150
288% 288%
134%
- Research and Development Expense 14 14
22% 22%
13%
-59 -59
4% 4%
-52%
- Depreciation and Amortization 0.61 0.61
917% 917%
1%
EBIT (Operating Income) EBIT -59 -59
5% 5%
-53%
Net Profit -48 -48
7% 7%
-43%

In millions USD.

Don't miss a Thing! We will send you all news about Silverback Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Silverback Therapeutics Stock News

Neutral
GlobeNewsWire
7 days ago
Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-world effectiveness of neffy is consistent with that historically reported for epinephrine injection SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- AR...
Neutral
GlobeNewsWire
18 days ago
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in pres...
Neutral
Seeking Alpha
about one month ago
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Eric Karas - Chief Commercial Officer Justin Chakma - Chief Business Officer Kathleen D. Scott - Chief Financial Officer Richard E.
More Silverback Therapeutics News

Company Profile

Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson on January 4, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Richard Lowenthal
Employees 165
Founded 2015
Website ars-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today